Israeli-based biotech company Trobix Bio has raised USD 3 million in a Series A extension round led by Chartered Group, a global private investment group. This brings the total funds raised to USD 6 million. 

The funds will be used to further develop the company's products, including TBX201, an orally available capsule designed to reduce the incidence and severity of severe diarrhea caused by irinotecan, and TBX301, an orally available capsule designed to reduce the incidence and severity of colitis in patients receiving immune checkpoint inhibitors. The funds will also be used to advance the TBX platform technology, which uses computational, synthetic, and synthetic biology technologies to engineer phages as medicines that reprogram targeted microbiome bacteria.

Trobix Bio is a biotech company that focuses on utilizing CRISPR, phage (viruses that infect bacteria), and synthetic biology technologies to develop precision microbiome oncology therapeutics. Trobix Bio operates a B2B business model as it partners with pharmaceutical companies to integrate its technology into their oncology treatments.